Centaurus Financial’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Centaurus Financial’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,800	Closed	-$114K	–	878
2024 Q2	$114K	Buy	+2,800	New	+$117K	0.01%	752
2024 Q1	–	Sell	-2,800	Closed	-$119K	–	867
2023 Q4	$119K	Buy	+2,800	New	+$80.5K	0.01%	716
2022 Q2	–	Sell	-3,000	Closed	-$105K	–	949
2022 Q1	$105K	Buy	+3,000	New	+$87.6K	0.01%	858

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Centaurus Financial's CERE Position: Q3 2024 in Review

Centaurus Financial sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 2,800 shares — an estimated $114K sold.

Centaurus Financial first reported a position in CERE in Q1 2022 and held it in 3 quarters. The position peaked at $119K in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Centaurus Financial reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Centaurus Financial sold 2,800 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $114K.
Centaurus Financial first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Centaurus Financial's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $119K in Q4 2023.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Centaurus Financial's 13F filing for Q3 2024, filed 12 Nov 2024.